Therapy Areas: Oncology
CStone Pharmaceuticals doses first Chinese patient in phase one clinical trial of CS1003
19 November 2018 -

CStone Pharmaceuticals, a biotechnology company, has enrolled and dosed its first patient in a phase one clinical trial in China for the recombinant humanised anti-programmed death-1 monoclonal antibody, CS1003, it is reported today.

This multi-centre Phase one clinical trial is evaluating the safety, tolerability and preliminary anti-tumour activity of CS1003 in Chinese patients with advanced cancers, led by the Beijing Cancer Hospital.

Dr Frank Jiang, chairman and CEO of CStone, said, 'CS1003 is an important IO backbone in CStone's pipeline and together with our PD-L1 monoclonal antibody (CS1001), is essential to our combination therapy strategy. We are happy to see Phase I trial get under way in China. We plan to carry out global development for this promising drug candidate as monotherapy and in combination with internal and external therapies to benefit cancer patients in China and globally.'

Login
Username:

Password: